All In Biotech

Drug Trial Radar · NCT07744126

A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 2 Open-Label Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Pembrolizumab as First-Line Treatment in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Oct 2029

Study completion Oct 2029

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with an annual incidence of approximately 700,000 cases. This study aims to evaluate the change in disease activity and optimal dose, and optimal dose of telisotuzumab adizutecan in combination with pembrolizumab as first-line treatment in participants with recurrent or metastatic head and neck squamous cell carcinoma. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of recurrent or metastatic HNSCC. Participants are placed into 3 treatment groups called treatment arms. Each group receives a different treatment. Adult participants diagnosed with recurrent or metastatic HNSCC who have not received prior systemic therapy for advanced disease and whose tumors express c-Met protein will be enrolled. Approximately 180 participants will be enrolled in the study at sites worldwide. Participants will receive intravenous doses of telisotuzumab adizutecan with intravenous pembrolizumab, or standard of care (SOC) chemotherapy with pembrolizumab. Participants will receive treatment as part of a 67 weeks study duration. There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits every 3 weeks during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • Telisotuzumab AdizutecanDrug

    Intravenous (IV)

  • PembrolizumabDrug

    IV

  • CarboplatinDrug

    IV

  • CisplatinDrug

    IV

  • FluorouracilDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 67 weeks
  2. Objective Response (OR) Rate Based on Blinded Independent Central Review Assessment per Response Evaluation Criteria in Solid Tumors Version 1.1Time frame: Up to Approximately 67 weeks
  3. Progression-Free Survival (PFS) Based on Blinded Independent Central Review Assessment per Response Evaluation Criteria in Solid Tumors Version 1.1Time frame: Up to Approximately 67 weeks

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • City Of Hope Comprehensive Cancer Center /ID# 281939

    Duarte, California · Recruiting

  • City of Hope - Atlanta /ID# 285268

    Newnan, Georgia · Recruiting

  • Kobe University Hospital /ID# 281770

    Kobe, Hyōgo, Japan · Recruiting

  • Saitama Medical University International Medical Center /ID# 282932

    Hidaka, Saitama, Japan · Recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 281506

    Kaohsiung City, Taiwan · Recruiting

  • China Medical University Hospital /ID# 281502

    Taichung, Taiwan · Recruiting

  • National Taiwan University Hospital /ID# 281513

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital /ID# 281531

    Taipei, Taiwan · Recruiting

  • Linkou Chang Gung Memorial Hospital /ID# 281529

    Taoyuan City, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.